Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.67 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8568554 | 1.00 | MCL1 (0.67) | MCL1SLC9A1MAPTOPRM1OPRL1 | |
| SCHEMBL6368871 | 0.84 | MCL1 (0.59) | MCL1SLC9A1MAPTOPRM1OPRL1 | |
| SCHEMBL16599480 | 0.82 | MCL1 (0.76) | MCL1SLC9A1MAPTMEN1NPC1 | |
| SCHEMBL117186 | 0.80 | MCL1 (1.00) | MCL1SLC9A1MAPTMEN1NPC1 | |
| SCHEMBL401039 | 0.80 | MCL1 (0.73) | MCL1SLC9A1MAPTMEN1NPC1 | |
| SCHEMBL31435640 | 0.79 | MCL1 (0.69) | MCL1ALDH1A1 | |
| SCHEMBL22022199 | 0.79 | RXFP1 (0.59) | MCL1MEN1KMT2AALDH1A1 | |
| SCHEMBL29623497 | 0.79 | MCL1 (0.53) | MCL1ALDH1A1SYK | |
| SCHEMBL17102355 | 0.79 | MCL1 (0.53) | MCL1ALDH1A1SYK | |
| SCHEMBL2323444 | 0.79 | MCL1 (0.71) | MCL1SLC9A1MAPTMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958850-B2 | Heteroaryl compounds for kinase inhibition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-16 | — | — | US | disclosed |
| US-20230102829-A1 | Heteroaryl Compounds For Kinase Inhibition | ARIAD PHARMACEUTICALS, INC. | 2023-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958850-B2 | Heteroaryl compounds for kinase inhibition | ERBB2, EGFR, ERBB3 | MCL1 544/4885SLC9A1 4684/4885MAPT 1164/4885 |
| US-20230102829-A1 | Heteroaryl Compounds For Kinase Inhibition | ERBB2, EGFR, ERBB3 | MCL1 544/4885SLC9A1 4684/4885MAPT 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.